Oxford Biomedica expands agreement with Cabaletta Bio
British CDMO Oxford Biomedica plc announces the expansion of its License and Supply Agreement with cell therapy specialist Cabaletta Bio, Inc. The new agreements adds CD19 as a new target - it originally covered Cabaletta Bios lead product, DSG3-CAART.
Philadelphia-based clinical-stage biotech Cabaletta Bio focuses on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases. The extension grants the US company a non-exclusive license to Oxford Biomedicas LentiVector platform for the its CAR-T programme, CABA-201, a fully human CD19-CAR T cell investigational therapy. Oxford Biomedica will receive an upfront payment of an undisclosed amount, although sources familiar with the matter have indicated a low double-digit million US dollar amount. The Oxford-based CDMO is also eligible for additional payments relating to the development and manufacture of lentiviral vectors for use in clinical trials, as well as certain development and regulatory milestone payments and an likewise undisclosed royalty on net sales of products that utilise the Companys LentiVector platform.
Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: “The expansion of our partnership with Cabaletta Bio stands as a testament to Oxford Biomedica’s unwavering commitment to quality and innovation. As a world-leading CDMO with expertise across all key viral vector types, we are committed to enabling our biopharma customers to discover and deliver transformative therapies. We’re excited to continue our work with Cabaletta and help them deliver accessible cures for patients with severe autoimmune disease.”
